Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.65 |
| ▸ | TERT | O14746 | 3/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | PPARD | Q03181 | 3/20 | 0.65 |
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | FABP4 | P15090 | 2/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774108 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL21544520 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL3038124 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL3038126 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL21544518 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL9809737 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL9751745 | 1.00 | HMGCR (1.00) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL5367963 | 0.95 | HMGCR (0.91) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL5367961 | 0.95 | HMGCR (0.91) | HMGCRPTPN7TERTPTPN1PPARG | |
| SCHEMBL5366848 | 0.90 | HMGCR (0.82) | HMGCRPTPN7TERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709348-A2 | PROMOTION OF HAIR GROWTH | CARBOCODE S.A. (PT) | 2026-03-18 | — | — | EP | claimed |
| US-12485085-B2 | PPAR agonist complex and methods of use | RODAN & FIELDS, LLC | 2025-12-02 | — | — | US | claimed |
| EP-4624449-A1 | VEGETABLE OIL CERAMIDES, SYNTHESIS METHOD THEREFOR, AND USE THEREOF | Shenzhen Dikeman Biotechnology Co., Ltd. (CN) | 2025-10-01 | — | — | EP | claimed |
| WO-2024236429-A2 | PROMOTION OF HAIR GROWTH | CARBOCODE S.A (PT) | 2024-11-21 | — | — | WO | claimed |
| US-12059486-B2 | Cosmetic compositions | Rodan &Fields, LLC (US) | 2024-08-13 | — | — | US | claimed |
| WO-2024109867-A1 | VEGETABLE OIL CERAMIDES, SYNTHESIS METHOD THEREFOR, AND USE THEREOF | 深圳市迪克曼生物科技有限公司 | 2024-05-30 | — | — | WO | claimed |
| EP-3500548-B1 | PROCESS FOR THE DECARBOXYLATIVE KETONIZATION OF FATTY ACIDS OR FATTY ACID DERIVATIVES | RHODIA OPERATIONS (FR) | 2023-05-10 | — | — | EP | claimed |
| US-20230000759-A1 | PPAR AGONIST COMPLEX AND METHODS OF USE | ANKURA TRUST COMPANY, LLC, IN ITS CAPACITY AS SUCCESSOR AGENT | 2023-01-05 | — | — | US | claimed |
| CN-110914356-B | Hydrophobized nanocellulose intermediate and production of hydrophobized nanocellulose | 分赛尔瑞典公司 | 2022-11-22 | — | — | CN | claimed |
| CN-109843843-B | Decarboxylative ketonization process for fatty acids or fatty acid derivatives | 罗地亚经营管理公司 | 2022-11-08 | — | — | CN | claimed |
| US-20050147631-A1 | Cosmetic composition and method for retarding hair growth | E-L MANAGEMENT CORP. | 2005-07-07 | — | — | US | claimed |
| WO-2005004890-A1 | COMBINATIONS OF VASOACTIVE AGENTS AND THEIR USE IN THE TREATMENT OF SEXUAL DYSFUNCTIONS | INDENA S.P.A. (IT) | 2005-01-20 | — | — | WO | claimed |
| US-20040115331-A1 | Ximenynic acid compositions, methods for their production and uses thereof | LODERS CROKLAAN B.V. (NL) | 2004-06-17 | — | — | US | claimed |
| EP-1402786-A1 | Ximenynic acid | LODERS CROKLAAN B.V. (NL) | 2004-03-31 | — | — | EP | claimed |
| EP-1402787-A1 | Ximenynic acid | LODERS CROKLAAN B.V. (NL) | 2004-03-31 | — | — | EP | claimed |
| EP-1402785-A1 | Ximenynic acid | LODERS CROKLAAN B.V. (NL) | 2004-03-31 | — | — | EP | claimed |
| US-6531563-B1 | Addition polymers based on reused raw materials used as seals, coatings, adhesives and/or fillers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-03-11 | — | — | US | claimed |
| EP-0693278-B1 | Combinations of vasoactive substances with fatty acids to prevent hair loss | INDENA SPA (IT) | 2002-06-05 | — | — | EP | claimed |
| US-5665335-A | Combinations of vasoactive substances with fatty acids to prevent hair loss | INDENA S.A. (IT) | 1997-09-09 | — | — | US | claimed |
| EP-0693278-A2 | Combinations of vasoactive substances with fatty acids to prevent hair loss | INDENA S.p.A. (IT) | 1996-01-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485085-B2 | PPAR agonist complex and methods of use | PPARG, PPARA, PPARD | HMGCR 116/4885PTPN7 1906/4885TERT 3318/4885 |
| US-20230000759-A1 | PPAR AGONIST COMPLEX AND METHODS OF USE | PPARG, PPARA, PPARD | HMGCR 116/4885PTPN7 1906/4885TERT 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.